A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer
This study is currently recruiting participants.
Verified September 2012 by University Health Network, Toronto
Sponsor:
University Health Network, Toronto
Collaborator:
Canadian Cancer Society
Information provided by:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01542177
First received: January 5, 2012
Last updated: September 18, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a diagnostic study to look for low levels of oxygen (hypoxia) in pancreatic cancer using an imaging test called positron emission tomography (PET). Hypoxia can influence how pancreatic cancer grows and responds to treatments such as chemotherapy and radiotherapy. The use of PET scans to measure hypoxia may be better and simpler than the approaches used previously. This study will assess whether or not PET scans using a tracer called 18F-FAZA (18F-Fluoroazomycin Arabinoside) can provide useful information about hypoxia in pancreatic cancer. Also as part of the study, a blood sample will be taken to study biomarkers (substances in the body that may be important indicators of hypoxia and/or pancreatic cancer) that may be useful in studying pancreatic cancer and hypoxia.
| Condition |
|---|
|
Pancreatic Cancer Hypoxia |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Evaluation of Hypoxia Imaging in Patients With Pancreatic Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA) |
Resource links provided by NLM:
Further study details as provided by University Health Network, Toronto:
Primary Outcome Measures:
- Measure the hypoxia level in Patients with Pancreatic Cancer using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA). [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Correlate FAZA PET uptake in pancreatic cancer with the extension of the disease. [ Time Frame: 2 years ] [ Designated as safety issue: No ]Standardized uptake statistics will be calculated for each volume of interest (VOI): Maximum standardized uptake value (SUVMax), mean standardized uptake value (SUVMean) and standard deviation of standardized uptake values (SUVSD).
- Correlate FAZA PET uptake in pancreatic cancer with CA 19-9 levels. [ Time Frame: 2 years ] [ Designated as safety issue: No ]Standardized uptake statistics will be calculated for each volume of interest (VOI): Maximum standardized uptake value (SUVMax), mean standardized uptake value (SUVMean) and standard deviation of standardized uptake values (SUVSD). These parameters will be correlated with increasing or decreasing CA 19-9 levels (U/ml).
- Correlate FAZA PET uptake in pancreatic cancer with tumor response. [ Time Frame: 2 years ] [ Designated as safety issue: No ]Standardized uptake statistics will be calculated for each volume of interest (VOI): Maximum standardized uptake value (SUVMax), mean standardized uptake value (SUVMean) and standard deviation of standardized uptake values (SUVSD). Tumor response is measured in millimeters. Complete response is a tumor reduction of <5 mm, partial response is at least a 30% reduction, progressive disease is a 20% increase, and stable disease is no increase in shrinkage and no increase in growth.
- Correlate FAZA PET uptake in pancreatic cancer with patient disease-free survival (DFS). [ Time Frame: 2 years ] [ Designated as safety issue: No ]Kaplan-Meier actuarial method and/or the Cox proportional hazard model will be utilized.
- Compare the pattern of FAZA uptake in different tumor sites (eg., lymph node metastases and liver metastasis). [ Time Frame: 2 years ] [ Designated as safety issue: No ]Standardized uptake statistics will be calculated for each volume of interest (VOI): Maximum standardized uptake value (SUVMax), mean standardized uptake value (SUVMean) and standard deviation of standardized uptake values (SUVSD).
- Determine the feasibility of using dynamic and static PET imaging of FAZA uptake in patients with pancreatic cancer. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Biospecimen Retention: None Retained
2 tubes of whole blood
| Estimated Enrollment: | 30 |
| Study Start Date: | February 2012 |
| Estimated Study Completion Date: | April 2015 |
| Estimated Primary Completion Date: | November 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Pancreatic cancer |
Detailed Description:
This is a single centre, single arm hypoxia study of pancreatic cancer with PET FAZA imaging.
PET-CT imaging of tumor hypoxia with FAZA will be done prior to the start of standard treatment for pancreatic cancer with chemotherapy. The FAZA PET-CT imaging session will last approximately 2.5 hours and include an initial dynamic scan to completely characterize the initial rapid phase of FAZA uptake, followed by a later static scan.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Pancreatic cancer
Criteria
Inclusion Criteria:
- Minimum age of 18 years old
- Histologic diagnosis of pancreatic adenocarcinoma
- TNM (7th edition) cT1-4, N0-1, M0-1
- No cytotoxic anti-cancer therapy for advanced / metastatic pancreatic cancer prior to study entry
- Ability to provide written informed consent to participate in the study
- ECOG performance status 0, 1 or 2.
- Patient should have the following blood counts at baseline: ANC equal or greater to 1.5 x 109/L; Platelets equal or greater to 100 x 109/L; Hgb equal or greater to 9g/Dl
- Patient should have the following blood chemistry levels at baseline: AST (SGOT), ALT (SGPT) equal or less than 5 x upper limit of normal range (ULN) is allowed
- Patient has an identifiable tumor (pancreatic tumor and/or metastasis) by imaging (CT scan and/or MR)
- Patient must agree to use contraception considered adequate and appropriate by the investigator and if the patient is female of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test (B-hCG)
Exclusion Criteria:
- Inability to lie supine for more than 30 minutes
- Any other type of primary cancer
- Life expectancy of less than 12 weeks
- Patient has known brain metastases unless previously treated and well controlled for at least 3 months (defined as stable clinically, no edema, no steroids and stable in two scans at least 4 weeks apart)
- Patient has serious medical risk factors involving any of the major organ systems
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01542177
Contacts
| Contact: Smitha Udagani | 416-946-4501 ext 3408 | smitha.udagani@uhn.ca |
Locations
| Canada, Ontario | |
| Princess Margaret Hospital | Recruiting |
| Toronto, Ontario, Canada, M5G 2M9 | |
| Principal Investigator: David Hedley, MD | |
Sponsors and Collaborators
University Health Network, Toronto
Canadian Cancer Society
Investigators
| Principal Investigator: | David Hedley, MD | Princess Margaret Hospital, Canada |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT01542177 History of Changes |
| Other Study ID Numbers: | FAZA-Pancreas |
| Study First Received: | January 5, 2012 |
| Last Updated: | September 18, 2012 |
| Health Authority: | Canada: Health Canada Canada: Ethics Review Committee |
Keywords provided by University Health Network, Toronto:
|
hypoxia pancreas cancer pancreatic cancer |
18F-FAZA 18F-Fluoroazomycin Arabinoside Positron Emission Tomography PET |
Additional relevant MeSH terms:
|
Pancreatic Neoplasms Anoxia Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms |
Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Signs and Symptoms, Respiratory Signs and Symptoms |
ClinicalTrials.gov processed this record on October 17, 2012
